Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women;Modificación de las concentraciones de C3 y C4 luego de la administración de estrógenos conjugados más medroxiprogesterona o raloxifeno en mujeres posmenopáusicas

Ginecologia y Obstetricia de Mexico

Volumn 73, Issue 10, 2005, Pages 521-524

  Carranza Lira, Sebastián ^a,c   MacGregor Gooch, Ana Luz ^a   Olivares, Aleida ^b   González Legorreta, Sandra Luz ^a   Saldívar, Nadia ^a   Martínez Chéquer, Juan Carlos ^b  

^a Hospital Luis Castelazo Ayala   (Mexico)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

^c NONE   (Mexico)

Author keywords

Complement; Conjugated equine estrogens; Inflammation; Medroxyprogesterone; Raloxifene

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ESTRADIOL; ESTROGEN; FOLLITROPIN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEIGHT; HUMAN; HUMAN EXPERIMENT; IMMUNOCHEMISTRY; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; WEIGHT; DRUG COMBINATION; DRUG EFFECT; ESTROGEN THERAPY; MIDDLE AGED;

COMPLEMENT C3; COMPLEMENT C4; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33745540951     PISSN: 03009041     EISSN: 03009041     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-9.
3. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.
4. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
5. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions in human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.
6. Miller AP, Chen YF, Xing D, et al. Hormone replacement therapy and inflammation. Interactions in cardiovascular disease. Hypertension 2003;42(part 2):657-63.
7. Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982;389:235-50.
8. Deppisch RM, Beck W, Goehl H, Ritz E. Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001;59(Suppl 78):S271-7.
9. Lagrand WK, Niessen HWM, Nijmeijer R, Hack CE. Role for complement as an intermediate between C-reactive protein and intercellular adhesion molecule-1 expression. Circulation 2001;104:E46.
10. Walport MJ. Advances in immunology. N Engl J Med 2001;344:1058-66.
11. Barrington R, Zhang M, Fischer M, Carroll MC. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001;180:5-15.
12. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-19.
13. Burke AP, Farb A, Malcolm G, Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J 2001;141:58-62.
14. Erlandsson MC, Gömöri E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000;205:103-9.
15. Bustillos-Camacho O, Martinez-Chéquer JC. Efecto de la terapia estrogénica de reemplazo sobre los nivelés séricos de complemento en la mujer posmenopáusica. [Tesis de posgrado] México: Hospital de Ginecología y Obstetricia Luis Castelazo Ayala - UNAM, 1998.